Cholangiocarcinoma
Conditions
Keywords
cancer, bile duct
Brief summary
This research study is a phase III double arm, multicenter, randomized controlled clinical trial comparing endoscopic retrograde cholangiopancreatography (ERCP) and stenting plus photodynamic therapy (PDT) versus ERCP with stenting alone in adult patients with unresectable cholangiocarcinoma. The study objectives are to investigate the efficacy of photodynamic therapy (PDT) in increasing the survival time of patients with unresectable cholangiocarcinoma and to assess the effect of PDT on both cholestasis and health-related quality of life (HRQoL).
Detailed description
The study objectives are to investigate the efficacy of photodynamic therapy (PDT) in increasing the survival time of patients with unresectable cholangiocarcinoma and to assess the effect of PDT on both cholestasis and health-related quality of life (HRQoL).
Interventions
PROCEDUREERCP and Photodynamic Therapy
Photodynamic Therapy is a new therapeutic approach that specifically targets neoplastic cells. This therapy has been used in other tumors as a local treatment and involves the intravenous administration of a photosensitizing agent followed by activation of the agent by illumination with non-thermal light of a specific wavelength, resulting in cell death from direct cytotoxicity and ischemic necrosis. Cytotoxicity is directly proportional to tissue oxygenation.
PROCEDUREERCP only
Endoscopic retrograde cholangiopancreatography and stenting.
Sponsors
Weill Medical College of Cornell University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient is age 18 years or older * Patient is diagnosed with non-resectable cholangiocarcinoma, as determined by CT within 30 days of enrollment and CT shows Bismuth Tumor Stage as: IIIa, IIIb, IV (Bismuth tumor stage I and II are not eligible to participate) * Patients must have adequate organ and marrow function as defined below: * Patient's INR ≤ 2 within 30 days of treatment * Patient's platelets \> 50,000/cmm within 30 days of treatment * Patient's Absolute Neutrophil Count (ANC) \> 1,500/cmm within 30 days of treatment * Patient's creatinine ≤ 3 mg/dL within 30 days of treatment * Patient has the ability to understand and the willingness to comply with the study procedures and provide written informed consent to participate in the study
Exclusion criteria
* Patient was diagnosed with cholangiocarcinoma more than 3 months ago * Patient has any metastatic disease * Patient has acute porphyria * Subjects exhibiting neurologic or cutaneous symptoms will undergo urinary delta-aminolevulinic acid and porphobilinogen dosage tests to determine severity. * Patient is pregnant (Women of child bearing age must have a negative pregnancy test prior to registration and must agree to use adequate contraception during study therapy) * Patient has a concurrent non solid malignancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Survival time in each group will be compared as well as effect of each treatment arm on cholestasis and HRQoL | 2.4 years |
Countries
United States
Outcome results
None listed